Zhongshan Hengsai Biotechnology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zhongshan Hengsai Biotechnology Co., Ltd. - overview
Established
2022
Location
Zhongshan, Guangdong, China
Primary Industry
Biotechnology
About
Based in Zhongshan, China, and established in 2022, Zhongshan Hengsai Biotechnology Co. , Ltd. is a medical company that focuses on the research and development of tumor therapy vaccines. It was recognized as the National High-Tech Enterprise.
Huining Liu, the founder and CEO of the company, graduated from Harvard Medical School and used to work for BMS and Quintiles. The company's R&D center and plant in Shanghai came into operation in 2021. In December 2025, Zhongshan Hengsai Biotechnology Co. , Ltd.
closed a strategic funding from new investor Tasly Holding Group. The company is committed to developing individualized dendritic cell tumor therapeutic vaccines (DC vaccine). It constructed the Eco-DCVax platform for the development of DC vaccine products. Products within include therapeutic dendritic cell vaccine, which can be used in the treatment of lymphoma, chronic viral infections, autoimmune diseases, and chronic active EB virus infection.
The company generates revenue from providing biotechnology services.
Current Investors
Fuho Capital, Triwise Capital, Zhongtong Financing Fund Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Zhongshan Hengsai Biotechnology Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | Zhongshan Hengsai Biotechnology Co., Ltd. | - | ||||||||
| Series A | Completed | Zhongshan Hengsai Biotechnology Co., Ltd. | - | ||||||||
| Series A | Completed | Zhongshan Hengsai Biotechnology Co., Ltd. | - | ||||||||
| Unspecified Round | Completed | Zhongshan Hengsai Biotechnology Co., Ltd. | - |
Displaying 1 - 4 of 4
Zhongshan Hengsai Biotechnology Co., Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.